Skip to content
Neuromyelitis News logo
  • About NMOSD
    What is NMOSD?
    Causes
    Symptoms
    Diagnosis
  • Treatments
    Approved treatments
  • News
  • Columns
    The Beginner’s Guide to Walking — Jennifer V.
    Archived Columns
    • Courage to Care — Candice Galvan
    • Strength of the Soul — Mileidys Almaguer Iniguez
    • The View From Here — Lelainia Lloyd
  • What can we help you find today?

March 21, 2023 News by Andrea Lobo

Enspryng’s Phase 4 trial favors new group of AQP4-NMOSD patients

A global Phase 4 clinical trial of Enspryng (satralizumab), approved to treat the most common form of neuromyelitis optica spectrum disorder (NMOSD), is enrolling newly diagnosed and other patients who could not or did not take part in Phase 3 trials of the therapy. In addition to people new…

October 14, 2021 News by Marta Figueiredo, PhD

#ECTRIMS2021 – Enspryng Prevents Relapses Over Long Term in Trials

Long-term treatment with Enspryng (satralizumab) safely and sustainably prevents relapses in adolescents and adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 protein (AQP4-IgG), according to four-year data from the SAkura Phase 3 clinical trials. These benefits were observed when the therapy…

Recent Posts

  • Study IDs 4 proteins as potential drug targets for treating NMOSD
  • Telehealth is a useful supplement to in-person appointments
  • Rituximab, MMF may be effective off-label options for NMOSD: Study
  • Thank you, readers, for reminding me of the power of community
  • Infection rates lower with Enspryng over other immunosuppressives
  • Surviving the storms of life with lessons I’ve learned from NMOSD
  • Late-onset NMOSD linked to worse recovery, faster disability
  • Returning to acupuncture for pain management after 14 years
  • Enspryng helps patients remain relapse-free after 6 months: Study
  • For me, preventing relapses involves harsh medication side effects


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.